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Introduction: Mutations in the lysosomal glucocerebrosidase (GBA) gene increase the risk of Parkinson's
Disease (PD). We determined the frequency and relative risk of major GBA mutations in a large series of
Italian patients with primary parkinsonism.
Methods: We studied 2766 unrelated consecutive patients with clinical diagnosis of primary degener-
ative parkinsonism (including 2350 PD), and 1111 controls. The entire cohort was screened for mutations
in GBA exons 9 and 10, covering approximately 70% of mutations, including the two most frequent de-
fects, p.N370S and p.L444P.
Results: Four known mutations were identiﬁed in heterozygous state: 3 missense mutations (p.N370S,
p.L444P, and p.D443N), and the splicing mutation IVS10þ1G>T, which results in the in-frame exon-10
skipping. Molecular characterization of 2 additional rare variants, potentially interfering with splicing,
suggested a neutral effect. GBAmutations were more frequent in PD (4.5%, RR ¼ 7.2, CI ¼ 3.3e15.3) and in
Dementia with Lewy Bodies (DLB) (13.8%, RR ¼ 21.9, CI ¼ 6.8e70.7) than in controls (0.63%). but not in
the other forms of parkinsonism such as Progressive Supranuclear Palsy (PSP, 2%), and Corticobasal
Degeneration (CBD, 0%). Considering only the PD group, GBA-carriers were younger at onset (52 ± 10 vs.
57 ± 10 years, P < 0.0001) and were more likely to have a positive family history of PD (34% vs. 20%,
P < 0.001).
Conclusion: GBA dysfunction is relevant for synucleinopathies, such as PD and DLB, except for MSA, in
which pathology involves oligodendrocytes, and the tauopathies PSP and CBD. The risk of developing
DLB is three-fold higher than PD, suggesting a more aggressive phenotype.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Mutations in the gene encoding beta-glucocerebrosidase (GBA,
OMIM *606463) are an important and common risk factor for
Parkinson's disease (PD). Many studies have shown an increased
frequency of GBA mutations in PD compared to controls [1,2]. In
particular, an odds ratio (OR) of approximately 5 has been found in
a multicenter study including approximately 5000 PD patients and
an equal number of controls [3]. GBA mutations were repeatedly
found to be increased also in Dementia with Lewy Bodies (DLB)
[4e6]. A recent multicenter study on 700 DLB patients reported ai Clinici di Perfezionamento,
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r Ltd. This is an open access articleremarkable OR of 8, suggesting that GBA mutations may have an
even larger role in the genetic etiology of DLB than in PD [7].
Furthermore, PD carriers of the GBA mutation are more likely to
progress to dementia, suggesting a signiﬁcant impact on the dis-
tribution of pathology and on the resulting clinical phenotype [8].
On the other hand, Multiple System Atrophy (MSA) does not appear
to be associated with GBA [9,10]. So far, no data are available on GBA
involvement in tauopathies, such as Progressive Supranuclear Palsy
(PSP) and Corticobasal Degeneration (CBD).
The frequency and distribution of GBA mutations vary among
populations, hindering comparisons between different patient se-
ries. Carrier frequency is quite high among Ashkenazi Jews (about 1
person in 14), and very rare in Asia [3]. In addition, studies were
usually performed on series of patients with the same diagnosis
often collected from many clinical centers, preventing the evalua-
tion of the importance of GBA in the different forms of
parkinsonism.
In this frame, we decided to analyze the major mutations in the
GBA gene in a large series of unrelated patients with primaryunder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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compare their frequency with a large control group from the same
population. This design enabled the evaluation and comparison of
GBA burden in various forms of parkinsonism in the Italian
population.
2. Methods
This study was approved by the local Ethical Committee and was conducted
according to the Declaration of Helsinki and to the Italian legislation on sensitive
personal data recording. Written informed consent was obtained from all subjects.
2.1. Subjects
We studied 2766 unrelated consecutive patients with degenerative parkin-
sonism, and 1111 controls, who contributed from 2002 to 2010 to the Parkinson
Institute Biobank (www.parkinsonbiobank.com), regardless of family history or age
at onset. All the patients had a diagnosis of primary degenerative parkinsonism:
2350 fulﬁlled current criteria for probable PD, 29 for DLB, 118 for MSA, 100 for PSP,
and 34 for CBD [11,12]. In particular, diagnosis of DLB was made only in those ful-
ﬁlling the 1-year rule between the onset of dementia and parkinsonism [13]. In the
remaining 135 cases, the clinical diagnosis was still uncertain and these patients are
reported here as suffering from undeﬁned primary parkinsonism (PKS). The ma-
jority of MSA cases (N ¼ 113) had been previously reported in a multicentre
collaborative study on GBA involvement in MSA [10]. Patients with suspect of sec-
ondary parkinsonism were excluded. All patients were examined by neurologists
expert in movement disorders. The following clinical and demographic data were
collected: gender, age at onset, asymmetry of symptoms at onset, disease duration,
education, cigarette smoking, and family history of PD. Among the 2350 PD patients,
the mean age at onset was 56.1 years (SD ± 10.9, range 13e87), the mean disease
duration was 11.6 years (SD ± 6.7, range 5e56).
Controls were recruited among spouses and caregivers and were unrelated to
the patients. All subjects who reported or showed signs or symptoms of movement
disorders or other neurodegenerative diseases were excluded. Among the 1111
controls, the mean age at sample collection was 62.3 years (SD ± 11; range 30e94
years). All controls denied any family history for movement disorders in ﬁrst-degree
relatives.
Except for 25 patients originating mainly from other European countries, all
patients and controls were of Caucasian ethnicity and Italian origin.
2.2. Mutation analysis
The mutational screening of GBA exons 9 and 10 was performed by a combi-
nation of high-resolution melting (HRM) analysis (exon 9) and direct DNA
sequencing (exon 10). PCR primer couples were designed on the basis of the known
genomic sequence of the gene (GenBank accession number NM_000157) to amplify
the two exons of interest and their exon-intron boundaries, avoiding the concomi-
tant ampliﬁcation of the highly-homologous GBA pseudogene (GBAP1)
(Supplementary Table 1). A detailed description of mutation analysis methods is
reported in the Supplementary material.
The 2350 PD patients were previously tested for several PD-related genes, such
as LRRK2 (G2019S, R1441 C/G, I2020L), Parkin, PINK1, DJ1, and SNCA [14e16]. The 66Table 1
GBA mutations/rare variants identiﬁed in 2766 patients with degenerative parkinsonism
Genomic positiona Rs ID cDNA changeb
1:155,205,659 NA c.1225-24T>G
1:155,205,634 rs76763715 c.1226A>G
1:155,205,581 rs149171124 c.1279G>A
1:155,205,440 NA c.1388 þ 32C>T
1:155,205,138 NA c.1389-36C>G
1:155,205,107 NA c.1389-5T>A
1:155,205,047 rs75671029 c.1444G>A
1:155,205,043 rs421016 c.1448T>C
1:155,204,985 NA c.1505G>T
1:155,204,978 rs371668537 c.1505C>A
All variants were identiﬁed in the heterozygous state. Frequent polymorphisms (minor
Seventeen of the 47 L444P mutations found in cases and two of the 3 found in control
recombinant allele).
Rs ID, refseq identiﬁcation number; NA, not available [variant not reported either in the HG
GO exome Sequencing Project (ESP, v.0.0.9 data release, November 2011, http://evs.gs.w
a According to UCSC Genome Browser (http://genome.ucsc.edu/, release Feb. 2009; GR
b According to mRNA Accession# NM_000157.3.
c Protein numbering omitting the signal peptide.
d Mutations already known to be responsible for Gaucher Disease.patients found to be carrier of mutations in these genes were not excluded from the
GBA genetic analysis.
2.3. Molecular characterization of the newly-identiﬁed splicing mutation
The effect of the IVS10þ1G>T splicing mutation on GBA pre-mRNA processing
was evaluated in RNA derived fromwhole blood of the carrier patient. Whole blood
was collected in a PAXgene Blood RNA Tube (PreAnalytiX, Hombrechtikon,
Switzerland) and RNA puriﬁcation performed by using the PAXgene BloodmiRNA kit
(PreAnalytiX) following the manufacturer's instructions. One microgram of total
RNA was reverse transcribed (RT) using random nonamers and the Superscript-III
Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). Of a total of 20 mL, 1 mL was
used as template for standard PCR reactions by means of exonic primers
(Supplementary Table 1). The identity of the ampliﬁed fragments was conﬁrmed by
Sanger sequencing. To quantify the relative amount of GBA exon-10 containing vs.
skipping isoforms, we performed competitive RT-PCRs by using a 6-FAM-labeled
primer. Ampliﬁed fragments were separated by capillary electrophoresis on an ABI-
3130XL Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and quantitated
by the GeneMapper v4.0 software.
2.4. Statistical analysis
All the following statistical procedures were performed using the R program
release 2.8.0 (http://www.r-project.org/).
For each GBA mutation, standard caseecontrol analyses on carrier frequency
data were performed with the Fisher exact test; all P values are presented as non-
corrected. The impact of GBA mutation burden on different clinical subtypes was
evaluated by the use of the relative risk (RR) statistics.
The association of different variables with the presence of GBA mutations in PD
patients was assessed by testing for differences between carriers and non-carriers
by means of a chi-square test for categorical data (i.e. gender, asymmetric onset,
smoking status, family history of PD), or by using the Student's t test for continuous
data (i.e. age at onset, disease duration, education; these were analyzed as a quan-
titative variable, after having veriﬁed that their departure from linearity was not
statistically signiﬁcant). The effect of each factor was expressed as the OR and 95%
conﬁdence interval (CI). Unadjusted ORs were obtained by using a logistic regression
model that included only the factor of interest; adjusted ORs were obtained by using
a model that included the factor of interest plus all of the factors that were signif-
icant in the ﬁrst step of analysis.
3. Results
3.1. Screening for GBA mutations on exons 9 and 10
In the whole cohort of subjects investigated (2766 patients and
1111 controls), we identiﬁed 10 different rare genetic variants, all
present in the heterozygous state (Table 1).
The p.N370S and p.L444P mutations were more common in
patients than in controls (2.5% vs. 0.36%, P ¼ 1.2  106 OR ¼ 7.1,
CI ¼ 2.6e19.5; and 1.7% vs. 0.27%, P ¼ 1.1  104 OR ¼ 6.4,
CI¼ 2.0e20.6, respectively) (Supplementary Table 2). In addition toand 1111 healthy controls.
Functionc Alleles in cases (n) Alleles in controls (n)
IVS8-24T>G 0 1
p.N370Sd 69 4
p.E388K 5 1
IVS9þ32C>T 1 0
IVS9e36C>G 0 1
IVS9-5T>A 1 0
p.D443Nd 1 0
p.L444Pd 47 3
IVS10þ1G>Td 1 0
IVS10þ8C>A 1 0
allele frequencies >2.5%) are not reported.
s were associated with the p.A456P variant (indicating the presence of a complex
MD professional, or in 5400 exomes obtained from the Exome Variant Server, NHLBI
ashington.edu/EVS/)].
Ch37/hg19 assembly).
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was found in more than one subject, with no difference between
cases and controls (0.18% vs. 0.09%, P ¼ 0.68). Therefore we
considered it a probable rare polymorphism. Indeed, E388K hasFig. 1. In-vivo analysis of the effect of the IVS10þ1G>T mutation on GBA preemRNA splici
resented by boxes (the thinner one corresponding to the 30 untranslated region) and intron
indicate positions of primers used in RT-PCR experiments. The position of IVS10þ1G>T is
products were obtained from RNA extracted fromwhole blood of the PD patient carrying the
separated on a 2% agarose gel; WM: molecular weight marker (lPstI). Two RT-PCR product
shorter one, of about 600 bp, possibly representing the transcript generated from the mutan
by the in-frame skipping of the 117-nucleotide-long exon 10. A schematic representation of t
experiments were also performed using, in the ampliﬁcation step, a ﬂuorescent primer. An
with GeneMapper v4.0 software. The ﬁgure shows a GeneMapper window displaying ﬂuor
empty peaks represent the size standard (ROX-500 HD; their length is indicated below the p
indicates GeneMapper data points and the Y-axis represents ﬂuorescence units (FUs). d) His
the sum of all the peak areas was set as 100%; the dark gray portion of the histogram corresp
whereas the light gray portion represents the percentage of wild-type isoforms. The exprenever been clearly associated to Gaucher Disease (GD) [17], while
has been found both in PD cases [5,18] and controls [19,20].
Other seven variants were found in individual cases (either pa-
tient or control). Among them, 2 were previously described asng. a) A schematic representation of part of the GBA gene is reported: exons are rep-
s by lines. The gene is approximately drawn to scale. Arrows below the relevant exon
indicated by an asterisk. b) The results of RT-PCR experiments are shown. Ampliﬁed
IVS10þ1G>T (c.1505þ1G>T) mutation, as well as from a healthy donor. Products were
s were concomitantly ampliﬁed: one corresponding to the wild-type transcript, and a
t allele. Direct sequencing of this aberrant product demonstrated that it is characterized
he two obtained RT-PCR products, together with their length, is also reported. c) RT-PCR
aliquot of the ﬂuorescent RT-PCR was run on a 3130XL Genetic Analyzer and measured
escence peaks corresponding to the 2 molecular species (wild type and mutant). The
anels), whereas the ﬁlled peaks correspond to the RT-PCR labeled products. The X-axis
tograms indicate the quantitative analysis on ﬂuorescence peak areas. For each sample,
onds to the percentage of transcripts containing transcripts lacking exon 10 (Dexon-10),
ssion of the mutant allele amounts to about one fourth of the wild-type allele.
Table 2
GBA mutation carriers according to clinical diagnosis.
Diagnosis Subjects
(n)
Carriers
(n)
% Of
subjects
RR (95% CI) P valuea
PD 2350 106 4.5% 7.2 (3.3e15.3) 2.2 £ 10¡11
DLB 29 4 13.8% 21.9 (6.8e70.7) 9.9 £ 10¡6
MSA 118 1 0.85% 1.3 (0.17e10.8) 0.56
PSP 100 2 2.0% 3.2 (0.67e15.1) 0.17
CBD 34 0 0% 2.1 (0.12e36.4) 0.99
Undeﬁned PKS 135 5 3.7% 5.9 (1.9e18.3) 5.9 £ 10¡3
Healthy controls 1111 7 0.63% / /
All the pathogenic mutations (p.N370S, p.D443N, p.L444P, IVS10þ1G>T) considered
together. RR was calculated considering healthy controls as reference group.
Signiﬁcant results are in bold.
Parkinson's disease (PD); Dementia with Lewy Bodies (DLB); Multiple System At-
rophy (MSA); Progressive Supranuclear Palsy (PSP); Corticobasal Degeneration
(CBD); Parkinsonisms (PKS).
a Statistics: Fisher exact test, two-tail.
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fessional, http://www.hgmd.org/], while the other 5 rare variants
were found in intronic regions (Table 1).
3.2. Molecular characterization of the identiﬁed splicing variants
Though previously described, the IVS10þ1G>T splicing muta-
tion has not yet been characterized from the molecular point of
view. Hence, to evaluate the effect of IVS10þ1G>T on GBA pre-
mRNA processing, a cDNA region spanning exons 7e11 was
ampliﬁed directly from mRNA of the carrier heterozygous patient.
Results suggest that IVS10þ1G>T is pathogenic through the skip-
ping of exon 10 (Fig. 1aeb). The GBA transcript skipping exon 10 is
predicted to code for a potentially non-functional protein, lacking
39 amino acids in the C-terminal portion of the enzyme.
The speciﬁc quantitative measurement of the mutant transcript
showed that the expression of the mutant allele amounts to only
about one ﬁfth of the wild-type allele, suggesting that the
aberrantly-spliced transcript might be unstable (Fig. 1ced).
Concerning all the remaining 5 intronic variants (IVS8-24T>G,
IVS9þ32C>T, IVS9e36C>G, IVS9-5T>A, IVS10þ8C>A), in-silico
analyses did not predict any signiﬁcant alteration of the splicing
process (e.g. activation of a cryptic splice site or abrogation of a
physiologic site; data not shown). Nonetheless, the IVS9-5T>A and
IVS10þ8C>A putative splice variants, both located within 10 nu-
cleotides from intron-exon junctions, were expressed in HeLa cells.Table 3
Cross-sectional analysis of demographic and general clinical features of 2284 consecutiv
Feature GBA carriers (n ¼ 102) Non-carriers (n ¼ 2
Male, n (%) 58 (56.9%) 1322 (60.6%)
Age at onset (y, mean ± SD) 51.54 ± 10.63 56.69 ± 10.51
Asymmetric onset, n (%) 78 (85.7%)b 1675 (85.1%)b
Disease duration (y, mean ± SD) 11.35 ± 7.315 11.87 ± 6.48
Education (y, mean ± SD) 10.70 ± 4.72c 9.80 ± 4.39c
Cigarette smoking, n (%) 39 (41.1%)d 797 (38.4%)d
Positive family history for PD, n (%) 21 (20.6%) 250 (11.6%)e
Values are expressed as counts (and %) or as mean ± standard deviation (SD). Signiﬁcan
The age at which the patient noticed the ﬁrst PD symptom was considered to be the a
amination. Education and smoking data are based on patient self-reporting. Current and fo
positive family history was restricted to patients having at least one 1st degree relative
a Variables were analyzed in a multivariate context throughmultivariate logistic regres
and non-carriers in the “crude” analysis), with the presence of GBA mutations as dichoto
b Percentage calculated on 91 carriers with available data and 1968 non-carriers.
c Value calculated on 98 carriers with available data and 2040 non-carriers.
d Percentage calculated on 95 carriers with available data and 2076 non-carriers.
e Percentage calculated on 2153 non-carriers with available data.Analysis of transcripts generated from constructs containing either
IVS9-5T>A or IVS10þ8C>A showed that exon 10 is correctly
included into the mature mRNA, demonstrating that both variants
are neutral (Supplementary Fig. 1).3.3. Frequency of GBA mutations
The frequency of GBA mutations according to clinical diagnosis
is reported in Table 2.
Pathogenic GBA mutations (p.N370S, p.D443N, p.L444P, and
IVS10þ1G>T) were signiﬁcantly increased in patients with PD, DLB,
and undeﬁned PKS, but not in those with MSA, PSP or CBD. The
highest RR was in DLB (RR ¼ 21.9, CI ¼ 6.8e70.7, P ¼ 9.9  106).
Five carriers (3.7%) occurred in the heterogeneous group of
patients with an undeﬁned PKS, containing all cases with a primary
parkinsonism whose clinical features did not fulﬁll currently
established consensus criteria [11e13]. All of them had parkin-
sonism (bradykinesia and rigidity) and co-occurring dementia,
while three out of 5 had poor response to levodopa.3.4. Genotype-phenotype correlations
We compared clinical phenotype between GBA-carriers and
non-carriers in the PD subgroup only, given the relatively low
number of carriers with other diagnoses (Table 3). We excluded
from this analysis those patients who were carriers of mutations in
other PD-related genes: 62 in the non-carrier group, and 4 in the
GBA-carrier group (LRRK2-p.G2019S, n ¼ 2; LRRK2-p.R1441C, n ¼ 1;
and homozygous deletion of exon 3 in parkin gene, n ¼ 1). An
extensive clinical description of these 4 PD patients is reported in
the online Supplementary material.
GBA-carriers had an earlier onset than non-carriers, with amean
age of 52 and 57 years, respectively. In particular, a total of 14/152
(9%) carriers had early onset (<40 years) compared to 88/2132 non-
carriers (4%). Moreover, carriers were more likely to have a positive
family history of PD (20.6% vs 11.6%).4. Discussion
In this study we analyzed a large case series of patients
consecutively collected at a single site, together with a large control
group, to evaluate the impact of the most frequent GBA mutations
in various forms of primary parkinsonism. GBA mutationse patients with PD according to GBA mutation status.
182) Unadjusted analysis Adjusted analysisa
P value Or (95% CI) P value Or (95% CI)
0.45 1.17 (0.78e1.74) e e
1.97 £ 10¡6 1.04 (1.03e1.06) 5.29 £ 10¡6 1.04 (1.03e1.07)
0.87 1.05 (0.58e1.91) e e
0.44 0.99 (0.96e1.02) e e
0.049 1.05 (1.00e1.09) 0.31 1.02 (0.98e1.07)
0.60 1.12 (0.74e1.70) e e
7.4 £ 10¡3 1.97 (1.20e3.25) 0.019 1.87 (1.11e3.15)
t values are in bold.
ge at onset of disease. Disease duration was calculated on the basis of the last ex-
rmer smokers were aggregated into the single category of smokers. The deﬁnition of
with a formal diagnosis of PD.
sion (adjusting for all covariates that resulted signiﬁcantly different between carriers
mous response variable.
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increase the risk for developing tauopathies (PSP and CBD).
Consistently with other European studies [3,19,20], the fre-
quency of GBA mutations in PD among our Italian patients is 4.5%,
conﬁrming that GBA mutations are the most common genetic
determinant of both familial and sporadic PD. However, in a pre-
vious study in the South of Italy, a lower frequency of mutations
was found in PD patients (11/395, 2.8%) and in controls (1/483,
0.2%), and the most common mutation was p.L444P [22].
Conversely, we found that the most frequent genetic defect is
p.N370S, as previously reported for Italian GD patients [23]. Our
Institute is located in the North of Italy; however, it is a tertiary
referral center and attending patients come from all parts of the
country. Therefore, the difference may be due to a particular fre-
quency of GBAmutations in Southern Italy or to the relatively small
size of the case series analyzed by DeMarco and colleagues [22].
A limitation of our study is that we screened only exons 9 and
10, and therefore we lost the carriers of rare mutations in other
regions of GBA. However, this screening strategy covers the vast
majority of GBA mutations in our population [20,23], and was
chosen to be able to analyze a large number of individuals.
The p.L444Pmutation, causing amore severe GD phenotype [23],
does not appear to be associated with a greater risk compared to the
less severe p.N370S (Supplementary Table 2), in contrast to what
previously reported [24,25]. This is relevant for genetic counseling.
Considering the p.L444P and the recombinant p.L444P þ p.A456P
alleles separately, only the non-recombinant allele is signiﬁcantly
associatedwith a higher PD risk. However, this is probably due to the
lower frequency of the p.L444P þ p.A456P variant.
Moreover, our study provides a precise assessment of GBA mu-
tation “carrier frequency” in the Italian population. Indeed,
considering that the 2 major mutations account for around 70% of
disease alleles, GBA mutation carriers including rare mutations
should be 0.9% of the general population, consistently with a
prevalence of GD in Italy of 1/40,000 [26].
Finally, we conﬁrm that in GBA-carriers the disease onset occurs
5 years earlier than in non-carriers [3], at difference with what
observed in our case series of LRRK2-mutated patients where age at
onset was similar between carriers and non-carriers [16]. It remains
to investigate the reason that why, although both genetic factors
operate in a multifactorial context, their effect on the phenotype is
expressed in a different way.
Considering other forms of parkinsonism, GBA mutations were
most common in DLB, where the highest RR was found. Although
our DLB cohort is too small to allow generalizations, this observa-
tion seems to conﬁrm the trend towards more widespread patho-
logical damage, even including the cortex and, consequently, the
increased risk for dementia in GBA mutation carriers [1]. Consis-
tently, the GBA-carriers amongst the patients categorized as un-
deﬁned PKS had not only parkinsonism, but also dementia. This
suggests that these patients are likely part of the Diseases with
Lewy Bodies spectrum, a continuum of clinic-pathologic entities
spanning from PD, PD and Dementia (PDD), to DLB [13]. In the
future, it will be interesting to verify whether our GBA mutation
carriers develop dementia more often than non-carriers, as sug-
gested by other studies [3,8].
Contrasting data on the frequency of GBA mutations in DLB
compared to PD have been reported: lower for some authors [6,18]
and higher for others [4,5]. In our analysis the frequency of GBA
mutations was clearly higher in DLB than in PD, with an RR (21.9),
which was considerably greater than in most studies. This may be
due to the low number of cases with diagnosis of DLB in our study
(note that the CI of the RR was 6.8e70.7), as well as to a selection
bias at our Institute, which focuses on PD. Indeed, the DLB patients
who have prominent dementia or dementia almost free fromparkinsonism probably do not come to our attention. GBA may be
more involved in forms with dementia with more important signs
of parkinsonism. Future research to explore this hypothesis may
focus on differences in cognitive and motor symptoms between
PDD and LBD carriers. Furthermore it may be interesting to evaluate
GBA mutation frequency within the LBD spectrum.
GBA mutations do not seem to play a role in the predisposition
both to MSA, as previously evidenced by us [10] and others [9], and
to tauopathies. This may underlie a different involvement of the
GBA-mediated lysosomal impairment in different forms of parkin-
sonism. Indeed, in neurons, the connection between beta-
glucocerebrosidase (GCase) impairment and Lewy bodies forma-
tion has been proposed to rely on GCase dysfunction leading to a-
synuclein accumulation in the lysosome, which in turns exacer-
bates loss of GCase activity [27]. Unlike other synucleinopathies,
the histopathologic hallmark ofMSA is accumulation of a-synuclein
within glial cytoplasmic inclusions (GCI) instead of within neurons.
At the beginning of the pathogenic process, a-synuclein accumu-
lates in the GCIs, located mainly within the oligodendroglial cells,
leading to neurodegeneration and, ultimately, neuronal death [28].
The evidence that GBAmutations are not associated with the risk of
developing MSA is in line with the hypothesis that the GCase
impairment does not play an important role in oligodendrocytes.
Similar conclusions can be drawn for PSP and CBD tauopathies,
inwhich to our knowledge GBAmutations have been sought for the
ﬁrst time. Indeed, although the mechanisms that lead to deposit of
tau protein are unclear [29], the GBA-mediated lysosomal impair-
ment does not seem to have a major role. This is of considerable
interest, in viewof the close correlation among a-synuclein, tau and
amyloid b pathologies [30].
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